The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Bogolepova A.N.

Pirogov Russian National Research Medical University;
Federal Center of Brain Research and Neurotechnologies of the Federal Medical Biological Agency

Makhnovich E.V.

Pirogov Russian National Research Medical University;
Federal Center of Brain Research and Neurotechnologies

Zhuravleva A.N.

Helmholtz National Medical Research Center of Eye Diseases

The relationship between cognitive impairment and changes in retinal neuroarchitectonics

Authors:

Bogolepova A.N., Makhnovich E.V., Zhuravleva A.N.

More about the authors

Read: 2493 times


To cite this article:

Bogolepova AN, Makhnovich EV, Zhuravleva AN. The relationship between cognitive impairment and changes in retinal neuroarchitectonics. S.S. Korsakov Journal of Neurology and Psychiatry. 2020;120(9):7‑13. (In Russ.)
https://doi.org/10.17116/jnevro20201200917

Recommended articles:
Cyto­kine status of patients with Alzheimer’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4-2):5-12
Differential diagnosis of Alzheimer’s disease and vascular cognitive diso­rders. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4-2):26-35
A comprehensive study of Alzheimer’s disease biomarkers in plasma and cere­brospinal fluid. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4-2):43-53
Prospects for treating Alzheimer’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4-2):54-60
Novel prospects for early diagnosis of cognitive impairment using Eye-tracking technology. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(6):13-20

References:

  1. Trofimov EO, Izvecov NV. Analysis of the market of drugs for the treatment of dementia in Russia. Remedium. 2019;9:16-25. (In Russ.). https://doi.org/10.21518/1561-5936-2019-9-16-25
  2. Gusev EI, Bogolepova AN. Cognitive disorders in cerebrovascular diseases. M.: Medpress-inform; 2013. (In Russ.).
  3. Bogolepova AN, Zhuravleva AN, Makhnovich EV. Prospects for diagnosing Alzheimer’s disease using optical coherence tomography. Zhurnal Nevrologii i Psihiatrii im. S.S. Korsakova. 2017;117(9):112-117. (In Russ.). https://doi.org/10.17116/jnevro201711791112-117
  4. Prince M, Albanese E, Guerchet M, Prina M. World Alzheimer Report 2014: Dementia and risk reduction an analysis of protective and modifiable factors. 2014;5(15):61-104.  https://www.alz.co.uk/research/WorldAlzheimerReport2014.pdf
  5. World Alzheimer Report 2015. The Global Impact of Dementia An analysis of prevalence, incidence, cost and trends. Published by Alzheimer`s Disease International (ADI). London. 2015. https://www.dementiaallianceinternational.org/wp-content/uploads/2015/08/World-Alzheimer-Report-2015-Summary-2015.
  6. Dementia. Who fact sheet. December 2018. (In Russ.). https://www.who.int/mediacentre/factsheets/fs362/ru
  7. Querfurth HW, LaFerla FM. Alzheimer’s disease. N Engl J Med. 2010;362(4):329-444.  https://doi.org/10.1056/NEJMra0909142
  8. Kivipelto M, Helkala EL, Laakso MP, Hänninen T, Hallikainen M, Alhainen K, Soininen H, Tuomilehto J, Nissinen A. Midlife vascular risk factors and Alzheimer’s disease in later life: Longitudinal, population basedstudy. BMJ. 2001;3:22:1447-1451. https://doi.org/10.1136/bmj.322.7300.1447
  9. Luchsinger JA, Gustafson DR. Adiposity, type 2 diabetes, and Alzheimer’s disease. J Alzheimers Dis. 2009;16:693-704.  https://doi.org/10.3233/JAD-2009-1022
  10. Colligris P, Perez de Lara MJ, Colligris B, Pintor J. Ocular manifestations of Alzheimer’s and other neurodegenerative diseases: The prospect of the eye as a tool for the early diagnosis of Alzheimer’s disease. J Ophthalmol. 2018;8538573:1-12.  https://doi.org/10.1155/2018/8538573
  11. Bogolepova AN, Makhnovich EV, Zhuravleva AN. Visual disorders and Alzheimer’s disease. Pharmateca. 2017; 2(4):13325-13373. (In Russ.).
  12. Braak H, Braak E. Evolution of neuropathology of Aizheimer’s and progression of AD as reflected by Braak stage 30, 37, 38 In disease. Acta Neurol Scand Suppl. 1996;165:3-12.  https://doi.org/10.1111/j.1600-0404.1996.tb05866.x
  13. Bogolepova AN. Sleep disorders and Alzheimer’s disease. Neurology, Neuropsychiatry, Psychosomatics. 2018;10(1):74-77. (In Russ.). https://doi.org/10.14412/2074-2711-2018-1-74-77
  14. Javaid FZ, Brenton J, Guo L, Cordeiro MF. Visual and ocular manifestations of AD and their use as biomarkers for diagnosis and progression. Front Neurol. 2016;7:55.  https://doi.org/10.3389/fneur.2016.00055
  15. Sadun AA. Axon caliber populations in the human optic nerve: change with age and disease. Int Neuro-Oph Society. 1986;7(5):5-20. 
  16. Katz B, Rimmer S. Ophthalmologic manifestations of Alzheimer’s disease. Surv Ophthalmol. 1989;34:31-43.  https://doi.org/10.1016/j.archger.2009.09.035
  17. Salamone G, Di lorenzo C, Mosti S, Lupo F, Cravello L, Palmer K, Musicco M, Caltagirone C. Color discrimination performance in patients with Alzheimer’s disease. Dement Geriatr Cogn Disord. 2009; 27(6):501-7. 
  18. Tzekov R, Mullan M. Vision function abnormalities in Alzheimer disease. Surv Ophthalmol. 2014;59:414-433.  https://doi.org/10.1016/j.survophthal.2013.10.002
  19. Liu D, Zhang L, Li Z, Zhang X, Wu Y, Yang H, Min B, Zhang X, Ma D, Lu Y. Thinner changes of the retinal nerve fiber layer in patients with mild cognitive impairment and Alzheimer’s disease. BMC Neurol. 2015;15(1):14. 
  20. Gehring WJ. The master control gene for morphogenesis and evolution of the eye. Genes Cells. 1996;1:11-5.  https://doi.org/10.1046/j.1365-2443.1996.11011.x
  21. Tuoc TC, Radyushkin K, Tonchev AB, Piñon MC, Ashery-Padan R, Molnár Z, Davidoff MS, Stoykova A. Selective cortical layering abnormalities and behavioral deficits in cortex-specific PAX6 knock-out mice. J Neurosci. 2009;29:8335-8349. https://doi.org/10.1523/JNEUROSCI.5669-08.2009
  22. Heins N, Malatesta P, Cecconi F, Nakafuku M, Tucker KL, Hack MA, Hack MA, Chapouton P, Barde YA, Gotz M Glial cells generate neurons: The role of the transcription factor Pax6. Nat Neurosci. 2002;5:308-315.  https://doi.org/10.1038/nn0502-500c
  23. Hinton DR, Sadun AA, Blanks JC, Miller CA. Optic-nerve degeneration in Alzheimer’s disease. N Engl J Med. 1986;315:485-487. 
  24. La Morgia C, Ross-Cisneros FN, Koronyo Y, Hannibal J, Gallassi R, Cantalupo G, Sambati L, Pan BX, Tozer KR, Barboni P, Provini F, Avanzini P, Carbonelli M, Pelosi A, Chui H, Liguori R, Baruzzi A, Koronyo-Hamaoui M, Sadun AA, Carelli V. Melanopsin retinal ganglion cell loss in Alzheimer disease. Ann Neurol. 2016;79:90-109.  https://doi.org/10.1002/ana.24548
  25. Hart NJ, Koronyo Y, Black KL, Koronyo-Hamaoui M. Ocular indicators of Alzheimer’s: exploring disease in the retina. Acta Neuropathol. 2016;132:767-787.  https://doi.org/10.1007/s00401-016-1613-6
  26. Alexandrov PN, Pogue A, Bhattacharjee S, Lukiw WJ. Retinal amyloid peptides and complement factor H in transgenic models of Alzheimer’s disease. Neuroreport. 2011;22:623-627.  https://doi.org/10.1097/WNR.0b013e3283497334
  27. Koronyo-Hamaoui M, Koronyo Y, Ljubimov AV, Ca M, Ko MK, Black KL, Schwartz M, Farkas DL. Identification of amyloid plaques in retinas from Alzheimer’s patients and noninvasive in vivo optical imaging of retinal plaques in a mouse model. Neuroimage. 2011;54(suppl 1):204-217.  https://doi.org/10.1016/j.neuroimage.2010.06.020
  28. Liu B, Rasool S, Yang Z, Glabe CG, Schreiber SS, Ge J, Tan Z. Amyloid-peptide vaccinations reduce β-amyloid plaques but exacerbate vascular deposition and inflammation in the retina of Alzheimer’s transgenic mice. Am J Pathol. 2009;175(5):2099-2110. https://doi.org/10.2353/ajpath.2009.090159
  29. He XF, Liu YT, Peng C, Zhang F, Zhuang S, Zhang JS. Optical coherence tomography assessed retinal nerve fiber layer thickness in patients with Alzheimer’s disease: a meta-analysis. Int J Ophthalmol. 2012;5(3):1-5. 
  30. Bambo MP, Garcia-Martin E, Gutierrez-Ruiz F, Pinilla J, Perez-Olivan S, Larrosa J M, Polo V, Pablo L. Analysis of optic disk color changes in Alzheimer’s disease: a potential new biomarker. Clin Neurol Neurosurg. 2015;132:68-73.  https://doi.org/10.1212/01.wnl.0000244490.07925.8b
  31. Bogolepova AN, Zhuravleva AN, Makhnovich EV. Prospects for diagnosing Alzheimer’s disease using optical coherence tomography. Journal of Neurology and Psychiatry. 2017;117(9):112-117. (In Russ.). https://doi.org/10.17116/jnevro201711791112-117
  32. Chan VT, Sun Z, Tang S, Chen LJ, Wong A, Tham CC, Lad EM. Spectral-domain OCT measurements in Alzheimer’s disease: a systematic review and meta-analysis. Ophthalmology. 2019;126(4):497-510.  https://doi.org/10.1016/j.ophtha.2018.08.009
  33. Thomson KL, Cameron JR, Pal S. A systematic review and meta-analysis of retinal nerve fiber layer change in dementia, using optical coherence tomography. Alzheimer’s Dement. Diagnosis, Assess. Dis Monit. 2015;1(2):136-143. 
  34. Fujino Y, Delucia MW, Davies P, Dickson DW. Ballooned neurones in the limbic lobe are associated with Alzheimer type pathology and lack diagnostic specificity. Neuropathology and Applied Neurobiology. 2004;30(6):676-682. 
  35. Reichenbach A, Wurm A, Pannicke T, Iandiev I, Wiedemann P, Bringmann A. Müller cells as players in retinal degeneration and edema. Graefe’s Archive for Clinical and Experimental Ophthalmology. 2007;245(5):627-636.  https://doi.org/10.1007/s00417-006-0516-y
  36. Knoll B, Simonett J, Volpe NJ, Farsiu S, Ward M, Rademaker A, Weintraub S, Fawzi AA. Retinal nerve fiber layer thickness in amnestic mild cognitive impairment: Case-control study and meta-analysis. Alzheimer’s Dement. 2016;4(2):85-93.  https://doi.org/10.1016/j.dadm.2016.07.004
  37. Erichev VP, Panyushkina LA, Fomin AV. Optical coherence tomography of the retina and optic nerve in the diagnosis of Alzheimer’s disease. Glaucoma. Journal of the research Institute GB RAMN. 2013;1:5-10. (In Russ.).
  38. Ascaso FJ, Cruz N, Modrego PJ, Lopez-Anton R, Santabárbara J, Pascual LF, Lobo A, Cristóbal JA. Retinal alterations in mild cognitive impairment and Alzheimer’s disease: an optical coherence tomography study. J Neurol. 2014;261(8):1522-1530. https://doi.org/10.1007/s00415-014-7374-z
  39. Turski GN, Schmitz-Valckenberg S, Holz FG, Finger RP. Retinal imaging of the macula and optic disc in neurodegenerative diseases. Der Ophthalmol. Zeitschrift der Dtsch. Ophthalmol Gesellschaft. 2017;14(2):114-119.  https://doi.org/10.1007/s00347-016-0412-8
  40. World Health Organization. Dementia:A Public Health Priority. Geneva: World Health Organization; 2012. Accessed March 21, 2018. https://apps.who.int/iris/bitsream/10665/75263/1/9789241564458_eng.pdf
  41. Paul RH. Vascular dementia: cerebrovascular mechanisms and clinical management. Springer Science. 2005;45(2):456-459. ID: 71837201.
  42. Kiseleva OA, Robustova OV, Bessmertny AM, Zakharova EK, Avdeev RV. Prevalence of primary glaucoma in representatives of different races and ethnic groups in Russia and CIS countries. Ophthalmology. 2014;10(4):11-15. (In Russ.).
  43. Gusev EI, Grechko VE, Burd GS. Nervous diseases. M.: Medicine; 1988. (In Russ.).
  44. Folstein MF, Folstein SE, McHugh PR. «Mini-mental state»: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12(3):189-198.  https://doi.org/10.1016/0022-3956(75)90026-6
  45. Nasreddine ZS, Phillips NA, Bédirian V, Charbonneau S, Whitehead V, Collin I, Cummings JL, Chertkow H. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005;53(4):695-699.  https://doi.org/10.1111/j.1532-5415.2005.53221.x
  46. Dubois B, Slachevsky A, Litvan I, Pillon B. The FAB: a frontal assessment battery at bedside. Neurology. 2000;55(11):1621-1626. https://doi.org/10.1212/WNL.55.11.1621
  47. Gharbiya M, Trebbastoni A, Parisi F, Manganiello S, Cruciani F, D’Antonio F, De Vico U, Imbriano L, Campanelli A, De Lena C. Choroidal thinning as a new finding in Alzheimer’s Disease: Evidence from enhanced depth imaging spectral domain optical coherence tomography. J Alzheimer’s Dis. 2014;40(4):907-917.  https://doi.org/10.3233/JAD-132039
  48. Berisha F, Feke G T, Trempe C L, McMeel J W, Schepens C L. Retinal abnormalities in early Alzheimer’s disease. Invest. Ophthalmol Vis Sci. 2007;48(5):2285-2289. https://doi.org/10.1167/iovs.06-1029
  49. Choi SH, Park SJ, Kim NR. Macular ganglion cell-inner plexiform layer thickness is associated with clinical progression in mild cognitive impairment and Alzheimers disease. Othtalm. 2016;11(9):16-22.  https://doi.org/10.1371/journal.pone.0162202
  50. Paquet C, Boissonnot M, Roger F, Dighiero P, Gil R, Hugon J. Abnormal retinal thickness in patients with mild cognitive impairment and Alzheimer’s disease. Neurosci Lett. 2007;420(2):97-99.  https://doi.org/10.1016/j.neulet.2007.02.090

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.